ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of

See also
Status	Clinical Trial	Phase
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Recruiting	`NCT06029218` - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy	N/A
Completed	`NCT00743496` - A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma	Phase 1
Recruiting	`NCT04337177` - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	Phase 1
Active, not recruiting	`NCT02945800` - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma	Phase 2
Recruiting	`NCT05968768` - To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)	Phase 2
Recruiting	`NCT06156410` - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma	Phase 1
Terminated	`NCT02536183` - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors	Phase 1
Recruiting	`NCT03715933` - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Phase 1
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT05093322` - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT02856048` - Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer	Phase 2/Phase 3
Withdrawn	`NCT03880123` - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	Phase 1
Completed	`NCT04956198` - Drug Sensitivity and Mutation Profiling
Recruiting	`NCT04791228` - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors	Phase 2
Recruiting	`NCT06068075` - Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD	N/A
Active, not recruiting	`NCT03709680` - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05734066` - Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT01807468` - Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors	Phase 2

NCT number	NCT02044120
Study type	Interventional
Source	Sarcoma Alliance for Research through Collaboration
Contact
Status	Completed
Phase	Phase 1
Start date	May 2014
Completion date	January 2021

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms